Abstract
Upper and lower respiratory infections are common triggers in patients with moderate to severe asthma, resulting in significant morbidity. Biologics are commonly used to treat asthma, but also known to impair the immune system, increasing the susceptibility of these patients to the SARS-CoV2 virus (COVID-19). We hypothesized that asthma patients on biologic have an increased incidence of COVID-19 infection compared to non-biologic asthma patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
